With an extensive presence in North America, Europe, South America, Australia, New Zealand and South Africa and more recently in the MENA and Asia Pacific region, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies. With a robust product portfolio in growth oriented therapies, such as Oncology, Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain management and Gastroenterology and over 5500 product approvals (as of April, 2015) in various markets, Accord’s sales, marketing and distribution network now reaches over 60 countries.
Within a short span of 6 years Accord Healthcare SAC has emerged as one of the fastest growing Indian Pharmaceutical Companies in Peru. Accord Healthcare SAC operates out of Lima, the 5th largest city in the Americas and is the Regional Office for Peru and the rest of Latin America (Central America and Caribbean Islands, Andean Countries, Paraguay & Argentina).
With a product portfolio of 31 products, Accord caters to the physicians’ need for therapy options focused on Gastroenterology, Urology and Oncology segments. Accord products are geared to meeting the patients’ expectation of quality medicines at competitive prices. Accord is proud to be one of the preferred suppliers of Government Institutions in Peru and caters to the unmet needs of the market in varied therapeutic areas. Accord has established its presence in both trade and tender markets of Peru and over the years has served all major Peruvian Government entities. Accord products conform to the increasing standards of regulatory requirements for the region.
As part of our growth in the region, Accord intents to launch various specialty generics that have a niche market in the region.
Contact details
Av. Manuel Olguín No. 215-217 Of. 1403
Torre Empresarial Omega
Santiago de Surco, Lima 33, Peru
+51 1 435 6735
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…
Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future…
Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top…
Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative,…
Massimiliano Rocchi, Managing Director at Accord Italy shares his view on the story behind Accord’s success in Europe, the key differentiating elements for any generics company in a market with…
Akhilesh Vijay came to Accord Healthcare Peru following a career at Intas Pharmaceutical in India. He urges the implementation of regulation for Biosimilars and discusses his strategy for future growth…
Many of the multinational companies with a long-standing presence in Latin America used to have factories in Peru – since the 1990s all of these companies have closed their facilities…
In modern terms, Peru’s healthcare system was largely underdeveloped for many years; but the economic fortune that Peru has experienced in more recent years has allowed for a significant overhaul…
Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels,…
Akhilesh Vijay came to Accord Healthcare Peru following a career at Intas Pharmaceutical in India. He urges the implementation of regulation for Biosimilars and discusses his strategy for future growth…
Seguro Integral de Salud (SIS) is the social protection scheme run under Peru’s Ministry of Health designed to provide health services to the country’s unemployed and poverty-stricken citizens. Its leader,…
Eurofarma entered the Peruvian market in 2013 through the acquisition of local player Refasa-Carrión. Rómulo García, the affiliate’s ambitious general manager, discusses the merge and his quest to become a…
Cesar Amaro, director general of Digemid, highlights the evolution of Peru’s recently-established regulatory agency while taking into account the challenges surrounding the institution on a daily basis, like approval times,…
Erbe Elektromedizin established its Peruvian representative office in 2013, the first in Latin America. Juan Otiniano, director of the affiliate, discusses the startup process and the importance of educating government…
Bomi Peru was incorporated in January 2014, amidst a number of new openings of the Italian logistics company. Andres Vazquez, commercial director, traces the evolution of the affiliate over the…
Induquímica is the only Peruvian pharmaceutical company with the “Marca Peru” emblem, a result of the company’s extremely high quality. General Manager Christian Quintanilla talks about the company’s success, and…
Luis Pinillos and Carlos Vallejos both served as Directors of INEN, the Cancer Institute and Minister of Health during President Garcia’s administrations. They discuss the achievements made before, during and…
Carolina López-Torres joined Hospira Peru in 2011 following a dynamic career at Novartis. She discusses the early challenges she faced and the opportunities that the government’s hospital expansion plan has…
See our Cookie Privacy Policy Here
